abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

Cette page n’est pas disponible en Français et est affichée en English

Article

25 Mai 2010

Auteur:
Marcus Baram, Huffington Post

Pfizer Rapamune Lawsuit: Pharma Giant's Subsidiary Accused Of Targeting 'High-Risk' Black Patients For Unapproved Use Of Drug [USA]

In a stunning whistleblower lawsuit, the world's largest pharmaceutical company is being sued over the dangerous practice of illegally promoting a kidney transplant drug for unapproved uses -- and targeting African-Americans, even though they are at high risk of complications...The suit claims: "Wyeth [part of Pfizer] trained and encouraged its sales representatives to market Rapamune for uses outside those listed on the [Federal Drug Administration]-approved label and to misrepresent and withhold clinical information regarding the safety and efficacy of Rapamune. As a result of Wyeth's wrongdoing, patients were put at risk of serious physical and financial harm..." Pfizer [said] "...We are very confident that the current promotional practices surrounding this product are fully compliant with all legal requirements..."